A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Galapagos Nv stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,411,000 shares of GLPG stock, worth $37.8 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares
1,411,000
Previous 1,411,000 -0.0%
Holding current value
$37.8 Million
Previous $35 Million 16.18%
% of portfolio
0.76%
Previous 0.73%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.2 - $42.44 $25.4 Million - $33.5 Million
788,888 Added 126.81%
1,411,000 $45.4 Million
Q4 2023

Feb 14, 2024

BUY
$31.87 - $40.71 $19.8 Million - $25.3 Million
622,112 New
622,112 $25.3 Million
Q3 2021

Nov 15, 2021

SELL
$52.17 - $70.2 $34.3 Million - $46.1 Million
-657,005 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$68.86 - $83.34 $45.2 Million - $54.8 Million
657,005 New
657,005 $45.3 Million
Q4 2019

Feb 14, 2020

SELL
$146.12 - $215.82 $14.8 Million - $21.8 Million
-101,010 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$111.45 - $128.93 $8.46 Million - $9.79 Million
-75,948 Reduced 42.92%
101,010 $13 Million
Q1 2019

May 15, 2019

SELL
$89.61 - $117.78 $9.99 Million - $13.1 Million
-111,449 Reduced 38.64%
176,958 $20.8 Million
Q4 2018

Feb 14, 2019

BUY
$87.81 - $110.65 $2.49 Million - $3.14 Million
28,343 Added 10.9%
288,407 $26.5 Million
Q3 2018

Nov 14, 2018

BUY
$90.63 - $120.22 $8.62 Million - $11.4 Million
95,064 Added 57.61%
260,064 $29.2 Million
Q2 2018

Aug 14, 2018

BUY
$88.4 - $105.34 $3.09 Million - $3.69 Million
35,000 Added 26.92%
165,000 $15.2 Million
Q3 2017

Nov 13, 2017

BUY
$73.17 - $103.47 $9.51 Million - $13.5 Million
130,000
130,000 $13.2 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.76B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.